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Ion channels are crucial elements in neuronal signal-
ing and synaptic transmission, and defects in their
function are known to underlie rare genetic disorders,
including some forms of epilepsy. A second class of
channelopathies, characterized by autoantibodies
against ligand- and voltage-gated ion channels, cause
a variety of defects in peripheral neuromuscular and
ganglionic transmission. There is also emerging evi-
dence for autoantibody-mediated mechanisms in sub-
groups of patients with central nervous system disor-
ders, particularly those involving defects in cognition
or sleep and often associatedwith epilepsy. In all auto-
immune channelopathies, the relationship between
autoantibody specificity and clinical phenotype is
complex. But with this new information, autoimmune
channelopathies are detected and treated with in-
creasing success, and future research promises new
insights into the mechanisms of dysfunction at neuro-
nal synapses and the determinants of clinical pheno-
type.
Introduction
Over the last 30 years, there has been increasing recog-
nition of the role that autoantibodies play in neurological
disorders. These mainly act on ligand-gated ion chan-
nels (receptors) and voltage-gated ion channels. This
has led to an emerging family of autoimmune channelo-
pathies that can be diagnosed by simple laboratory
tests and, in the main, respond well to immunotherapies
that reduce the levels of the pathogenic autoantibodies.
Many of these channels are mutated in genetic disor-
ders, but these conditions, of course, are not associated
with autoantibodies and do not respond to immunolog-
ical treatments.
This review will start with a few words about the im-
mune system and how it can be involved in the patho-
physiology of neurological disease. The immune system
consists broadly of primary lymphoid organs (thymus,
bone marrow), secondary lymphoid organs (lymph
nodes and spleen), and lymphocytes and antigen-pre-
senting cells, some of which circulate in the blood
and/or are found patrolling or sessile in nonlymphoid or-
gans of the body. The macrophages, dendritic cells, and
*Correspondence: angela.vincent@imm.ox.ac.ukother antigen-presenting cells present short peptide se-
quences (epitopes) derived from foreign antigens to
specific T cells (with the peptide within a grove on the
surface of a human leukocyte antigen (HLA) molecule
so that it can interact with the highly specific T cell re-
ceptor). The T cells become activated and are able to di-
rect the immune response against the cells that express
the HLA-epitope sequence, or to direct the synthesis of
antibodies (immunoglobulins, first IgM and then IgG)
against other epitopes on the antigen. The immuno-
globulin genes are able to undergo rearrangement and
somatic mutation leading to maturation of the B cell re-
sponse and persistence of those that make the highest-
affinity antibodies. Although the main role of the immune
system is to protect against infection, this can have un-
fortunate consequences if the immune response cross-
reacts with target antigens in the host, or if the
expression of microbial antigens within cells leads to
T cell- or macrophage-mediated damage. This is partic-
ularly the case when the immune response initiates an
inflammatory infiltration in the antigen-expressing tis-
sue, and if the antibodies activate the serum comple-
ment components that lead to cell lysis.
Immune diseases of the nervous system include those
that are associated with infections, such as HTLV-1-as-
sociated encephalopathy and HIV-AIDS-associated en-
cephalitis, and those in which an inflammatory response
against the brain is caused by unknown mechanisms,
such as multiple sclerosis. In each of these conditions
the balance between cellular (T cell)- and humoral (anti-
body)-mediated mechanisms is not always clear and
may vary between individual patients.
Autoantibodies in Neurological Diseases
Neurological diseases associated principally with auto-
antibodies to various antigenic targets can be divided
broadly into two groups: those in which the antibodies
are markers for an inflammatory process and those in
which the antibodies are directly pathogenic. This dis-
tinction is important for the clinicians, since the latter
diseases are, in general, easier to treat. Autoantibodies
are traditionally measured by indirect immunohisto-
chemistry on the target tissue, followed by western blot-
ting, identification of the target antigen by molecular
techniques, and development of an ELISA or other labo-
ratory test for measuring antibodies to the defined anti-
gen. This approach has been very fruitful for the study of
the autoantibodies that are found in a proportion of pa-
tients with paraneoplastic neurological disorders. These
conditions are defined as those in which the neurologi-
cal disease is secondary to the presence of a tumor
but is not directly caused by the tumor itself. They result
from the immune response that is generated against the
tumor, which can usually be shown to express the neu-
ronal antigen; the resulting T cells and autoantibodies
crossreact with neuronal tissue. The autoantibodies in-
dicate that the patient has a tumor, but they are not usu-
ally directly pathogenic, as the antigenic target is often
intracellular (but see voltage-gated calcium channels,
below). The neurological disorder in these patients is
Neuron
124Figure 1. Diagrammatic Representation of
the Neuromuscular Junction Showing the
Various Ion Channels and Interacting
Proteinsthought to be caused by a T cell-mediated attack on the
neurons expressing the antigen, and the associated in-
flammation that this produces (Bataller and Dalmau,
2004).
By contrast, autoantibodies to ion channels and other
functional membrane proteins may not be detected by
immunohistochemistry and usually do not bind well on
western blots of denatured tissue, but are measured
with high specificity and sensitivity by immunoprecipita-
tion of the native protein extracted from appropriate
tissue by gentle detergent and tagged with radioactively
labeled neurotoxins, or of the protein expressed by re-
combinant technology in mammalian cell lines, purified
and tagged directly with 125I or 35S. In addition, recent ad-
vances include binding of serum antibodies to the sur-
face of mammalian cell lines expressing cloned channels.
Autoimmune Channelopathies
at the Neuromuscular Junction
The neuromuscular junction (NMJ) serves as a prototype
synapse with well-defined pre- and postsynaptic com-
ponents that express ion channels with well-described
identity (Figure 1). Diseases that interfere with function
at the NMJ lead to muscle weakness or muscle hyperac-
tivity (Table 1). They can be caused by neurotoxic poi-
soning (e.g., botulism, snake bite) but in the western
world the most common cause is autoimmunity, and
the prototypic disease is myasthenia gravis (MG). Here
we will first briefly discuss current understanding of
the role of autoimmunity in MG, and then how this
has led to recognition of new antibody-mediated chan-
nelopathies in the peripheral, autonomic, and central
nervous systems. For a detailed review of MG, see
Drachman (1994).
Myasthenia Gravis
MG usually presents after puberty, and patients first pre-
senting in older age (>50 years) are increasingly recog-
nized. It is a chronic disease, and spontaneous remis-
sions are infrequent. The patient complains of muscle
weakness and fatigue that may first affect the ocular
muscles with diplopia (double vision) and ptosis (droop-
ing of the eyelids). However, individual patients can have
very different patterns and severity of weakness. Weak-
ness may remain in the ocular muscles (ocular MG) orspread to the facial, bulbar, and respiratory muscles
(bulbar MG) or also involve the limbs (generalized MG).
Choking and respiratory failure can be life threatening.
The weakness classically gets worse with repetition
and improves with rest or with use of acetycholinester-
ase inhibitors (which increase the amount of ACh in the
synaptic cleft at the neuromuscular junction).
The account of how myasthenia gravis became recog-
nized as an autoimmune disease is told elsewhere (Vin-
cent, 2002). The most crucial events were the active
immunization of rabbits against acetylcholine receptors
(AChRs) purified from the electroplax of electric eel,
which induced muscle weakness and paralysis. This
was phenotypically similar to MG and shown to be due
principally to antibodies that crossreacted with the rab-
bit’s muscle AChR and reduced the number of func-
tional AChRs (Patrick and Lindstrom, 1973). This model
of MG, experimental autoimmune MG (EAMG), has been
reproduced in many other species and consistently in-
volves an antibody-mediated mechanism with no direct
contribution from T cell immunity, as shown by transfer
of disease to normal animals by injection of serum or IgG
antibodies. Contemporaneously, it was shown that the
number of AChRs was reduced at the NMJs of MG pa-
tients using radioactively labeled a-bungarotoxin (Fam-
brough et al., 1973; Ito et al., 1978). Antibodies to human
AChR were present in patients with MG (Lindstrom et al.,
1976), these antibodies could passively transfer disease
to mice (Toyka et al., 1975), and removal of the IgG
antibodies from MG patients by plasma exchange led
to marked clinical improvement (Newsom-Davis et al.,
1978).
Thymic Pathology and Disease Heterogeneity
MG is associated with thymic pathology. Young adult
patients (<50 years), usually female, frequently have an
enlarged thymus that contains germinal centers very
similar to those normally restricted to lymph nodes
and spleen. These younger patients often carry the
HLA antigen haplotype B8DR3 (Compston et al., 1980).
In the medulla, close to the germinal centers, there are
muscle-like ‘‘myoid’’ cells that express AChR (Schluep
et al., 1987), and epithelial cells of the thymic cortex ex-
press individual AChR subunits (e.g., Salmon et al.,
1998) and other muscle genes (Mesnard-Rouiller et al.,
2004). Some of the germinal centers contain B cells
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125Table 1. Ion Channel and Related Targets in Antibody-Mediated Diseases
Ion Channel or
Related Protein
Associated Autoimmune
Disease(s) Main Clinical Features Location
Genetic Defects
also Found?
a1 nicotinic acetylcholine
receptor (AChR)
myasthenia gravis muscle weakness
and fatigue
neuromuscular junction congenital myasthenic
syndromes
Muscle-specific kinase
(MuSK)
myasthenia gravis
without AChR
antibodies
muscle weakness
and fatigue
neuromuscular junction one case of congenital
myasthenic syndrome
P/Q-type (a1A) voltage-
gated calcium channel
(VGCC)
Lambert Eaton
myasthenic syndrome
muscle weakness presynaptic nerve
terminal at
neuromuscular junction
congenital myasthenic
syndrome not yet
identified, but subtle
defects in transmitter
release in spontaneous
mouse mutants and
a1A knockouts
P/Q-type (a1A) voltage-
gated calcium channel
(VGCC)
lung cancer-associated
cerebellar ataxia
ataxia presynaptic nerve
terminal at central
synapses
familial hemiplegic
migraine, episodic
ataxia type 2, and
spinocerebellar ataxia
type 6
Voltage-gated potassium
channel (VGKC) Kv1
subtypes
acquired neuromyotonia muscle fasciculations,
cramps,
pseudomyotonia,
hyperhydrosis
presynaptic nerve
terminal at
neuromuscular junction
epilepsy, episodic
ataxia type 1 (Kv1.1)
with myokymia
Voltage-gated potassium
channel (VGKC) Kv1
subtypes
limbic encephalitis memory loss,
confusion, seizures,
personality change,
psychiatric features
presynaptic nerve
terminal at central
synapses
Kv1.1 knockout
mice are seizure
sensitive and have
memory impairment
a3 nicotinic acetylcholine
receptor (a3 AChR)
autoimmune autonomic
neuropathy
orthostatic hypotension,
impaired pupil
responses, urinary
retention
autonomic ganglia knockout mice
have marked
autonomic dysfunctionspecific for AChR (Roxanis et al., 2002) and produce
AChR antibodies (Scadding et al., 1981), and serum
AChR antibody levels decline to some extent after re-
moval of the thymus. These surprising findings probably
reflect the fact that many autoantigens, or epitopes of
them, are normally expressed in thymic medulla cells
where they should lead to deletion of those T cells that
might become reactive against self-antigens, but in
MG this process fails and the T cells become activated
instead. Older patients, however, are more frequently
male and are not associated with this HLA antigen,
and their thymuses are normally involuted.
In addition, about 10% of MG patients have a thymic
tumor. These tumors are associated not only with MG
but also with other neurological diseases (see below).
The patients always have AChR antibodies but also of-
ten have antibodies to interferon-a and interleukin-12
(Shiono et al., 2003; Yoshikawa et al., 2006). More de-
tailed discussions of the role of the thymus in MG can
be found elsewhere (Marx et al., 1997).
Mechanisms of AChR Loss
Autoantibodies to AChRs are found in the majority of MG
patients, very infrequently in healthy individuals or other
diseases, and are thought to be directly pathogenic. The
AChR is a pentameric membrane protein. AChR anti-
bodies are high affinity, mainly IgG1 subclass, react var-
iably with AChR extracted from muscles of other spe-
cies and, most importantly, bind mainly to extracellular
epitopes of the native AChR, which are available to cir-
culating antibodies (Vincent et al., 1987). Because these
epitopes are conformation dependent, the antibodies
bind poorly to denatured AChR, to recombinant sub-
units, or to the peptide sequences. Their specificity fordifferent sequences of the AChR subunits therefore
has been derived by competition experiments with
monoclonal antibodies raised against purified AChR or
against recombinant subunits (Tzartos et al., 1981). A
variable proportion bind to a region on each of the two
AChR a subunits called the main immunogenic region,
which includes aa 64–76 (Tzartos et al., 1988, 1998),
but some bind to other epitopes on the a subunits or
on the other subunits (Whiting et al., 1986).
The weakness in MG is caused by loss of the AChRs at
the neuromuscular junction, probably compounded by
morphological damage to the motor endplate. This
means that the postsynaptic depolarization (endplate
potential) resulting from each nerve impulse is too small
to achieve the critical firing threshold required for open-
ing of sufficient voltage-gated sodium channels to initi-
ate an action potential in the muscle fiber. As a result,
the safety factor for transmission is compromised. The
mechanisms by which the antibodies lead to loss of
AChRs was investigated in detail in the late 70s and early
80s. Although the MG sera often reduced the binding of
125I-a-bungarotoxin to AChR in solution or to mouse
muscle cell lines in culture (Drachman et al., 1982), there
are relatively few studies that show that the antibodies
can reduce AChR function at the neuromuscular junc-
tion (Weinberg and Hall, 1979; Burges et al., 1990). A re-
versible block of function can be achieved by some MG
IgG preparations applied to AChR-expressing cells
in vitro, which may lead over time to a more persistent
block, but it is not clear how important this is to muscle
in vivo (Jahn et al., 2000; Figure 2).
A more important mechanismproposed was increased
turnover of the AChR. The MG antibodies reduced the
Neuron
126number of surface AChRs in cell lines in a temperature-
and time-dependent manner (e.g., Heinemann et al.,
1977), and this effect could be prevented by cleaving
the antibodies into monovalent Fab fragments (Drach-
man et al., 1978). These and many other studies indicated
that cross-linking of the AChRs by divalent IgG and sub-
sequent internalization and degradation of the AChRs
was a major mechanism, at least in vitro, and was inde-
pendent of serum complement factors. To prove that
this could also occur in vivo, passive transfer experi-
ments were performed by injecting the MG IgG anti-
bodies and measuring the turnover of the AChRs in vivo
(Stanley and Drachman, 1978; Wilson et al., 1983a).
A third mechanism is complement activation by the
IgG1 and IgG3 antibodies (these subclasses are strong
complement activators) with lysis of the postsynaptic
membrane and morphological damage (Engel et al.,
1977; Sahashi et al., 1978, 1980). Complement-depen-
dent lysis is likely to be an important mechanism, since
the damage will not only reduce the number of AChRs
and the available membrane for insertion of new AChRs,
but also affect the number and distribution of the volt-
age-gated sodium channels that are concentrated at
the bottoms of the postsynaptic folds (Figure 1). This
would lead to further difficulties in achieving the post-
synaptic depolarization required to initiate the muscle
action potential, as demonstrated in both MG biopsies
and EAMG muscle (Ruff and Lennon, 1998). In the
EAMG model, complement inhibitors protect against
disease (Piddlesden et al., 1996), and muscles deficient
Figure 2. Direct Block of Function by MG IgG Preparation on Mouse
Myotube Patches
Block was reversible by washing during the first few minutes but in-
creasingly became irreversible over 60 min. Recordings were made
from outside-out patches with single pulses of 1 mM acetylcholine
(ACh) applied at 0.25 Hz before, during, and after incubation periods
of 50, 120, 600, and 1800 s with the IgG (see horizontal bars). Taken
with permission from Jahn et al. (2000).in complement regulators may be more susceptible (Ka-
minski et al., 2004). The evidence for each of the three
mechanisms is summarized in Table 2.
Compensatory Mechanisms and Phenotypic
Variability
Like most biological systems, the NMJ tries to limit the
physiological defect resulting from disease mecha-
nisms. First, an increase in gene expression for the
AChR subunits (Guyon et al., 1998) and synthesis rates
of AChRs (Wilson et al., 1983b) indicates postsynaptic
compensatory mechanisms in the human disease, and
also in the animal model (Asher et al., 1993). Second,
an increase in quantal release from the motor nerve
terminal, correlating with the reduced amplitude of the
miniature endplate potentials (Plomp et al., 1995), sug-
gested retrograde signaling from the postsynaptic mus-
cle to the presynaptic nerve terminal. However, the time
course of these changes in individual endplates is un-
known, and the mechanisms are largely unexplored. In
chronically a-bungarotoxin-treated rats, used as a
model of MG, the quantal content became sensitive to
inhibitors of CaM KII and some tyrosine kinases, sug-
gesting that the expression of these, or their ability to
affect the quantal content, was altered (Plomp and Mo-
lenaar, 1996). Since nNOS is anchored postsynaptically
at the neuromuscular junction (Kusner and Kaminski,
1996), NO is a potential retrograde signal.
Within an individual, AChR antibody levels correlate
with disease severity during treatments (Newsom-Davis
et al., 1978), but antibody levels between patients are
highly variable and do not correlate well with severity.
This raises the possibility that individual differences in
the specificity of the antibodies, or the existence of an-
tibodies to other NMJ antigens, might also play a role.
In addition, the compensatory changes mentioned
above might differ between individual’s muscles and
help to explain the considerable variability in severity
and distribution of muscle weakness that is common
in MG. Another factor, recently recognized in experi-
mental MG models, is a possible role of rapsyn (Hoede-
maekers et al., 1998). This cytoplasmic protein is essen-
tial for the clustering of AChRs under the presynaptic
motor nerve terminal (Figure 1) and appears to help sta-
bilize the AChRs during autoimmune attack (Losen et al.,
2005). Different expression levels of rapsyn, and ability
of the muscle to upregulate its expression (or that ofTable 2. Disease Mechanisms in Autoantibody-Mediated Diseases
Disease Antigenic Target Direct Block of Function
Increased Internalization
and Degradation
Complement-Mediated
Damage
Myasthenia gravis acetylcholine receptor
(AChR)
reversible block shown
by IgG preparations
but not evident from
most earlier studies
time- and temperature-
dependent loss of
receptors; divalent
antibodies necessary
IgG and complement
deposits, morphological
damage
Fetal arthrogryposis fetal-form acetylcholine
receptor (AChR)
shown by in vitro
experiments, not reversible
possible but
not necessary
no evidence; unlikely as
complement levels low
Lambert Eaton
myasthenic
syndrome
P/Q-type (a1A)
voltage-gated calcium
channel (VGCC)
rare examples of reversible
reduction in quantal release
time- and temperature-
dependent loss of
VGCC currents; divalent
antibodies necessary
no evidence of
complement deposition
or damage
Neuromyotonia voltage-gated potassium
channel (VGKC) subtypes
Kv1.1, -1.2, and -1.6
no effect on VGKC currents
during acute incubations in
cell lines and HEK-expressing
Kv1.1 and -1.6
time- and temperature-
dependent loss of
VGKC currents; divalent
antibodies necessary
no biopsy data available
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127Figure 3. Maternal Antibodies to Fetal AChR
Cause Developmental Disorder
(A) Effect of IgG preparation from a mother of
babies with fatal arthrogryposis on ACh-in-
duced currents. ACh was applied in pulses
(short bars) before and after a 40 min applica-
tion of IgG at 1:50 dilution (filled section of
bars). The IgG dramatically inhibited currents
through the fetal AChR but not through adult
AChR. Taken with permission from Rie-
mersma et al. (1996).
(B) A diagram of the adult and fetal forms of
AChR.
(C) Passive transfer of this developmental dis-
order to mice. A mouse taken at term from
a dam injected with plasma from a mother of
babies with arthrogryposis is shown on the
left. The mouse was paralyzed and hardly
breathing. Many of the limb joints are fixed
in abnormal positions. On the right is a mouse
taken at term from a dam injected with plasma
obtained from a mother of healthy babies.
Taken with permission from Jacobson et al.
(1999).other molecules not yet studied) during autoimmune at-
tack, could be other factors that affect disease expres-
sion in the human disease.
Fetal AChR, Maternal Antibodies, and Development
The AChR exists in a fetal and adult form (Figure 3) dif-
fering only in the presence of the g (fetal) or 3 (adult) sub-
unit. Fetal AChR is expressed during development and
in humans is replaced by adult AChR in the last weeks
of intrauterine life (contrasting with mice, where replace-
ment is not complete until around postnatal day 15). Fe-
tal AChR is upregulated in denervated muscle and is
expressed at low levels in adult human muscle (Ma-
cLennan et al., 1997) and at some NMJs in the multiply
innervated extraocular muscle fibers (Kaminski, 1998),
and also in the myoid cells of the thymus (see above). In-
deed, antibodies that compete with monoclonal anti-
bodies specific for fetal AChR (Whiting et al., 1986) are
not uncommon in MG patients, and in some instances,
these antibodies do directly inhibit ACh-induced cur-
rents or reduce miniature endplate potentials (Weinberg
and Hall, 1979) probably by binding to a site on the g
subunit overlapping the ACh-binding site.
Many female patients with MG develop the disease
before pregnancy, and one could predict that these an-
tibodies would be harmful to the developing fetus. A
transient form of MG occurring in the neonate and due
to transfer of maternal antibodies is well recognized. Ar-
throgryposis multiplex congenital (multiple bent joints)
can be caused by any condition that limits fetal move-
ment in utero. It can be associated with other life-threat-
ening deformities (e.g., lung hypoplasia). A few cases of
arthrogryposis were identified in which there were ma-
ternal antibodies specific for fetal AChR. In some of
these cases, the mother did not have any evidence of
MG herself but suffered recurrent fetal loss, stillbirths,
or early termination because of ultrasound evidence of
severe deformities in utero (reviewed by Polizzi et al.,
2000). The maternal antibodies inhibited ACh-induced
currents (Figure 3) and Na+ ion fluxes through fetal butnot through adult AChRs (Riemersma et al., 1996), and
passive transfer of maternal antibodies to pregnant
mice resulted in a high proportion of paralyzed and de-
formed offspring (Figure 3; Jacobson et al., 1999). These
cases are rare, representing about 1.5% of cases of
arthrogryposis (Dalton et al., 2006), but highlight the pos-
sibility that this and other developmental or neurodevel-
opmental disorders (e.g., autism; Dalton et al., 2003)
might be caused by maternal antibodies. There are
a few other instances in which maternal antibodies are
thought to be responsible for fetal deformities (e.g.,
Rothenberg et al., 2004).
MG without AChR Antibodies
About 15% of MG patients do not have AChR anti-
bodies, yet these patients respond to immunotherapies,
and their serum or plasma antibodies can transfer a de-
fect in neuromuscular transmission to mice, indicating
that they also have an antibody-mediated condition
(Mossman et al., 1986). Subsequent studies suggested
that a serum IgG (Bufler et al., 1998) or non-IgG compo-
nent, possibly IgM, reduced ACh-induced Na+ ion flux or
ACh-induced currents (Yamamoto et al., 1991; Barrett-
Jolley et al., 1994; Plested et al., 2002), and it was pro-
posed that these putative antibodies might act via an in-
direct second messenger pathway that was associated
with increased AChR desensitization in the presence of
agonist. A possible target could be a NMJ specific re-
ceptor that acted as a receptor for tyrosine or other
kinases. MuSK (muscle-specific kinase), which is a
NMJ-specific receptor tyrosine kinase (Valenzuela
et al., 1995), was a possible candidate. MuSK is essen-
tial during development of the NMJ when it orchestrates
the agrin-induced clustering of fetal AChRs under the
developing motor nerve terminal (Sanes and Lichtman,
1999). Antibodies to MuSK were found in up to 70% of
MG patients without AChR antibodies (Hoch et al.,
2001; Scuderi et al., 2002); the antibodies bound to
MuSK expressed in intact cell lines and were able to
inhibit agrin-induced clustering in C2C12 cell lines.
Neuron
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tially stimulated agrin-independent clustering, perhaps
because they bind divalently to MuSK, leading to its
dimerization and activation.
MuSK antibodies were found to be IgG, not IgM, and
their presence did not correlate with that of the AChR in-
hibitor activity of the sera (Plested et al., 2002), so they
do not explain the putative IgM-mediated increased de-
sensitization of the AChR described above. MuSK anti-
bodies are found in only a proportion of patients without
AChR antibodies and extremely infrequently in those
with AChR antibodies, suggesting that they define a dis-
tinct form of MG. The patients often have severe bulbar
dysfunction that can be difficult to treat effectively with
immunosuppression. The reasons for this are not clear,
but muscle atrophy of facial and tongue muscles is com-
mon (Farrugia et al., 2006), and it is possible that MuSK
antibodies induce muscle atrophy, particularly in certain
muscles. Preliminary findings using C2C12 mouse myo-
tube cultures suggest that MuSK antibodies can upre-
gulate MuRF-1, a muscle atrophy-related gene product
(Glass, 2003), and that MuRF-1 is upregulated in mouse
masseter muscle after passive transfer with MuSK anti-
bodies (Benveniste et al., 2005).
It is still not clear how MuSK antibodies cause MG. The
NMJs in biopsies from MuSK patients do not show loss of
AChR or complement deposition (Shiraishi et al., 2005),
reflecting the fact that the antibodies are mainly in the
IgG4 subclass (McConville et al., 2004), which does not
activate complement. There have been few electrophys-
iological studies on patients’ muscles, and in one the
miniature endplate potentials were reduced despite
a normal number of AChRs (Selcen et al., 2004). This is
analogous to findings in mouse muscle after passive
transfer of patients’ sera (Mossman et al., 1986; Burges
et al., 1994) and suggests that the antibodies may affect
function directly, perhaps by alteration of MuSK-depen-
dent downstream signaling events. Interestingly, a new
MuSK-interacting protein, called Dok-7, has recently
been discovered (Okada et al., 2006). Mutations in the
DOK7 gene are found in patients with a genetic form of
limb-girdle myasthenia in which the NMJs are small but
with relatively normal levels of AChRs (Beeson et al.,
2006; Slater et al., 2006). Some of the clinical features in
these patients resemble somewhat those of the MuSK
antibody patients, tentatively suggesting that loss of
downstream signaling from MuSK may be a common
mechanism. There have been two reports of animal
models induced by immunization against MuSK (Shige-
moto et al., 2006; Jha et al., 2006), but the mechanisms
at the NMJ are not yet clearly defined.
The patients without either AChR or MuSK antibodies
remain an enigma. However, based on the possibility
that the putative IgM antibodies might bind directly,
but with low affinity, to the AChR, and the fact that sim-
ilar electrophysiological findings occurred with binding
of a monoclonal antibody C7 to the AChR delta subunit
(Spreadbury et al., 2005), we have began to look for low-
affinity AChR antibodies in MG sera. Some of the previ-
ously AChR antibody-negative patients have antibodies
that bind to cell lines expressing high concentrations of
AChR on their surface but do not bind to the AChR in
solution (M. Leite, J. Cossins, D. Beeson, N. Willcox,
and A.V., unpublished data).Lambert Eaton Myasthenic Syndrome—A Voltage-
Gated Calcium Channelopathy
The findings in myasthenia were crucial in leading the
way to identification of further autoimmune channelopa-
thies and provided clinical and experimental criteria that
helped to define them (Table 3). The Lambert Eaton my-
asthenic syndrome (LEMS) is another disorder in which
muscle weakness is the predominant symptom but dif-
fers from MG in that the weakness is more common in
the trunk and limbs, less frequentlyaffects the facialmus-
cles, and may improve rather than worsen with repetitive
activity (Eaton and Lambert, 1957). Many of the patients
have autonomic symptoms, and about half have a small
cell lung cancer (O’Neill et al., 1988).
Seminal investigations in the 1950s and 1960s
showed that the defect was presynaptic, with marked
reductions in the quantal content (number of ACh
packets released per nerve impulse) and that the ACh
release increased with high-frequency nerve stimulation
or by raising extracellular calcium (Lambert and Elmqv-
ist, 1971; Elmqvist and Lambert, 1968). These observa-
tions suggested that a reduction in the influx of calcium
into the motor nerve terminal might underlie the disease
mechanism. Later freeze-fracture studies showed that
the active zone particles on the presynaptic membrane,
generally considered to be the voltage-gated calcium
channels (VGCC), were reduced in numbers and formed
into small aggregates rather than into the normal double
parallel arrays (Fukunaga et al., 1983). The crucial evi-
dence that the disease was autoimmune followed the
demonstration that the majority of patients responded
well to immunomodulatory therapy and that the disease
could be passively transferred to mice. Injection of IgG
(daily for 3 or more days) transferred the electrophysio-
logical features of the disease, reduced quantal content
and increased sensitivity to extracellular calcium (Lang
et al., 1987), and changes in the number and distribution
of active zone particles (Fukuoka et al., 1987a, 1987b;
Engel et al., 1989). These observations clearly impli-
cated VGCCs as a target antigen in the disease.
VGCCs are a family of multimeric ion channels with
different biophysical and pharmacological properties.
The a1 subunit comprises the main calcium pore and de-
termines the functional subtype (P/Q, N, L, R, or T) and
sensitivity to various neurotoxins. Therefore, it was pos-
sible to use specific neurotoxins that label subtypes of
the VGCC, to demonstrate antibodies in patients with
LEMS (using the same general approach as that em-
ployed for AChR antibodies in MG). Antibodies were first
detected in 40%–50% of patients using 125I-conotoxin
GVIA (125I-CgTx) from Conus geographus (Sher et al.,
1989) to label N-type VGCCs extracted in digitonin
Table 3. Criteria for Autoimmune Diseases
Suggestive
Usually adult onset of disease
History of autoimmunity in patients or their families
HLA association
Strongly Suggestive of Antibody-Mediated Disease
Antibodies that bind to extracellular domain of membrane protein
Clinical improvement following plasma exchange
Passive transfer of disease to experimental animal
by injection of IgG
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(A) Representative current traces taken from three a1A cells incubated either with LEMS IgG, control IgG, or medium alone.
(B) Only IgGs from LEMS patients reduced the current density. Other neurological disease (OND) or healthy control IgGs did not cause significant
reductions on one-way ANOVA. Results shown are mean 6 SEM. Taken with permission from Pinto et al. (2002).
(C–F) The effect of control and LEMS IgG on the whole-cell calcium currents in cultured Purkinje cells (after 13 days culture in vitro). Represen-
tative time courses and traces from control IgG-treated Purkinje cells (C and D) and LEMS IgG-treated Purkinje cells (E and F) exposed to u-Aga
IVA,u-CgTx GVIA, and nifedipine are shown. Pretreatment with LEMS IgG causes a marked reduction in theu-Aga IVA-sensitive calcium current.
Taken with permission from Pinto et al. (1998).from a human neuronal cell line. However, antibodies
that bind to the N-type VGCC (encoded by the a1B)
are not thought to be functionally effective, and some
at least bind to intracellular determinants, including the
b subunit (Verschuuren et al., 1998).
Subsequently, using 125I-conotoxin MVIIC (125I-CmTx)
from C. magus, antibodies to mammalian P/Q-type
VGCC antibodies were demonstrated in >85% of
LEMS patients (Motomura et al., 1995; Lennon et al.,
1995). The P/Q-type VGCC antibodies are present in pa-
tients with or without small cell lung cancer (SCLC).
SCLC cells express functionally active VGCC on their
surface, and Ca2+ influx through these channels is in-
hibited by incubation in IgG from LEMS patients (Rob-
erts et al., 1985). Presumably, therefore, the body’s
immune response to the tumor leads to antibodies di-
rected at these VGCCs, which then crossreact with
those at the NMJ to cause the neurological disease.
Thus, SCLC-associated LEMS is a condition in which
antibodies secondary to the presence of a tumor are
causative, rather than merely a marker for the associ-
ated tumor. However, VGCC antibodies can also be
found at low levels in some patients with lung cancer
without peripheral neurological dysfunction, including
SCLC-associated cerebellar ataxia (Graus et al., 2002).
In these cases, the antibodies are probably acting as
markers for the presence of the tumor rather than play-
ing a pathogenic role, since the patients do not generally
improve with immunosuppressive therapies. The cause
of LEMS in the patients without cancer is not clear.
There have been few experiments to dissect the anti-
genic epitopes of VGCC antibodies. An antigenic site lo-
cated on an extracellular region (domain III in the S5-S6
linker) of the a1A subunit of the P/Q-type VGCC is recog-nized by 50% of LEMS patients (Takamori et al., 2000),
but it is not clear what proportion of patients’ antibodies
bind to this epitope and whether these antibodies are
particularly pathogenic. Some patients’ sera also bind
to synaptotagmin (Takamori et al., 1995), and immuniza-
tion against VGCC and synaptotagmin peptides has in-
duced some of the electrophysiological changes of
LEMS (Takamori et al., 1994).
Mechanisms of VGCC Loss and Compensatory
Mechanisms
The antibodies reduce K+-stimulated Ca2+ influx in cell
lines (Roberts et al., 1985), but these effects take hours
to develop and are dependent on cross-linking by diva-
lent antibody and independent of complement (Peers
et al., 1990; see Table 2). The specificity of the anti-
bodies for different VGCCs and their in vitro functional
effects were studied using HEK cells expressing individ-
ual VGCC subtypes (Pinto et al., 1998, 2002). IgG from all
LEMS patients tested bound to the a1A (P/Q-type) cell
line, and overnight incubation in LEMS IgG caused
a dose-dependent reduction in the K+-stimulated Ca2+
influx into the a1A but not the a1B, a1C, a1D, or a1E
cell lines. Only 2/6 LEMS sera bound to the a1B (N-
type) VGCC, but neither of these patients’ sera reduced
the whole-cell calcium currents in these cells. Similarly,
overnight incubation in LEMS antibodies reduced the
P-type component of voltage-dependent currents in
cultured rat Purkinje cells, and P- and Q-type currents
in cultured rat granule cells, without affecting N-type
VGCC currents. A concomitant upregulation in residual
(R-type) VGCC current was observed in both of these
cultured cells (Figure 4). These results strongly suggest
that LEMS IgG binds to multiple subtypes of VGCC but
only functionally downregulates the P/Q subtype and
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of other subtypes. Recently, Buchwald et al. (2005), us-
ing a ‘‘macro-patch clamp’’ technique, demonstrated
a reduction in quantal release from the motor nerve ter-
minal during incubation in LEMS Ig, implying that there
may be a more direct blocking effect in some patients.
The compensatory changes seen in cultured cerebel-
lar cells are also likely to be important in vivo. In mice
passively transferred with LEMS IgG over 9 days, there
was not only a decrease in the quantal content, but
also a corresponding increase in the sensitivity of trans-
mitter release to the L-, N-, and R-type VGCC (Giovannini
et al., 2002). Whether these channels are present under
normal conditions and unmasked, or whether they are
newly synthesized during the passive transfer process,
has not been determined (Giovannini et al., 2002). More-
over, do they replace the P-type channels in the active
zones, which seems unlikely from the LEMS freeze-frac-
ture studies, or are they expressed elsewhere on the
presynaptic nerve terminal?
One of the striking features of LEMS is the autonomic
dysfunction that can be disabling. Patients frequently
have dry mouth, constipation, erectile impotence, and
urinary problems. While it was initially thought that N-
type VGCCs were most important in controlling the re-
lease of ACh at the autonomic synapses (Lundy and
Frew, 1993), P/Q- and/or R-type VGCCs are also in-
volved, and the precise combination of VGCC subtypes
appears to vary according to the neurotransmitter, tis-
sue, and species (Waterman, 2000). In the passive trans-
fer model, all LEMS IgG tested was capable of downre-
gulating P/Q-type VGCC, and again the downregulation
of the P/Q-VGCC was mirrored by an upregulation in
other channels (R- and to a lesser degree N-type) (Wa-
terman et al., 1997).
It is interesting to compare the effects of the anti-
bodies with those of genetic ablation in the VGCC. a1A
subunit-deficient mice (a1A
2/2) died 4 weeks postnatal,
after developing a rapidly progressive ataxia and dysto-
nia (Jun et al., 1999). P- and Q-type currents in Purkinje
and cerebellar granule cells were absent in the a1A
2/2
mice, whereas the L- and N-type VGCC channels were
elevated in Purkinje cells. Moreover, transmission in hip-
pocampal slices was spared in these mice, the lack of
P/Q channels being at least partially compensated for
by a rise in N and R channels (Jun et al., 1999). Similar
findings were shown at the NMJs (Urbano et al., 2003).
Thus, compensatory changes occur in both autoim-
mune and genetic channelopathies.
a3 Ganglionic AChR Antibodies in Autoimmune
Autonomic Neuropathies
A subgroup of patients with autonomic disturbance
have a monophasic illness that develops over days or
weeks, persists for some months, and then may partially
recover. The symptoms can affect both the sympathetic
and parasympathetic systems with orthostatic hypoten-
sion, impaired sweating, dry mouth and eyes, sexual
dysfunction, urinary retention, impaired pupillary re-
sponses, and defects in control of heart rate. There
may also be gastrointestinal disturbance such as
constipation or diarrhea.
Vernino and colleagues hypothesized that there might
be antibodies to the ganglionic form of AChR and wereable to demonstrate these in a proportion of patients
(Vernino et al., 2000) using radioactively labeled epibati-
dine to tag the a3- and b4-containing form of nicotinic
AChR, which is present at ganglionic synapses of the
autonomic system. Mice lacking the a3 subunit lack au-
tonomic ganglia and have severe autonomic dysfunc-
tion with prominent mydriasis (Xu et al., 1999). Evidence
for the pathogenicity of these antibodies is now strong.
The titer correlates with the degree of autonomic impair-
ment not only within an individual patient but also be-
tween patients (in which respect it contrasts with
AChR antibodies in MG). Active immunization has led
to a convincing animal model of the disease (Lennon
et al., 2003), and a single injection of the rabbit or human
antibodies into mice leads to autonomic dysfunction,
which lasts for a few days and, interestingly, is followed
by a compensatory overshoot in function as the mice re-
cover (Vernino et al., 2004).
Voltage-Gated Potassium Channelopathies
Acquired Neuromyotonia
A spectrum of diseases is associated with muscle hy-
peractivity or stiffness. Some are genetic (see Kleopa
and Barchi, 2002) whereas others are autoimmune.
The disorders that arise from peripheral nerve hyperex-
citability include neuromyotonia and cramp-fascicula-
tion syndrome (Hart et al., 2002). Acquired neuromyoto-
nia typically presents with muscle fasciculations and
cramps, stiffness, myokymia, pseudomyotonia (delayed
relaxation of contracted muscles), and hyperhydrosis
(increased sweating). The limb and trunk muscles are
most commonly affected. Up to 20% of patients also
have sensory symptoms such as paraesthesias, sug-
gesting that sensory as well as motor nerves may be
hyperexcitable (Lance et al., 1979).
Electrophysiologically, the patients’ muscles show
spontaneous and repetitive (doublet, multiplet) dis-
charges of single motor units with variably high intra-
burst frequency. This neuromyotonic activity has been
blocked in every case by local curare and variably by
nerve block (Isaacs and Heffron, 1974; Newsom-Davis
and Mills, 1993), indicating that it originates in the motor
nerve rather than in the muscle itself. Recent electro-
physiological studies provide evidence that the most
distal portion of the nerve close to the NMJ is where hy-
perexcitability usually develops (Arimura et al., 2005;
Maddison et al., 2006). Cramp-fasciculation syndrome
is probably a milder version of the same condition, and
the distinction from neuromyotonia lies in their electro-
myographic and clinical features: neuromyotonic dis-
charges are not detected in the cramp-fasciculation
syndrome (Hart et al., 2002).
Like MG, NMT can be associated with other autoim-
mune diseases, including MG, rheumatoid disease, sys-
temic lupus erythematosus, diabetes mellitus, and
others (Newsom-Davis and Mills, 1993). Acquired NMT
can also be a paraneoplastic syndrome, associated
with thymoma in 10%–20% of cases, and more rarely
with small cell lung carcinoma, Hodgkin’s lymphoma,
and other malignancies. NMT patients improve with
plasma exchange and other immunosuppressive treat-
ments, and passive transfer of IgG antibodies to mice
resulted in resistance to curare (Sinha et al., 1991), a
modest increase in quantal content and prolonged
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131action potentials in sensory nerves (Shillito et al., 1995).
One IgG preparation tested caused repetitive activity in
dorsal root ganglion cultures. Overall, the results were
very similar to those obtained with low concentrations
(50 mM) of the potassium channel blockers 3,4-diamino
pyridine or 4-amino-pyridine. Immunoprecipitation of
125I-dendrotoxin-VGKCs extracted from human or rabbit
cortex demonstrated antibodies to VGKCs in about 40%
of patients, although the antibody levels are not very
high, and the test is less robust than that for AChRs or
VGCCs (Shillito et al., 1995). Dendrotoxin only binds to
the Kv1.1, 1.2, and 1.6 members of the Shaker-type po-
tassium channels. Immunostaining of Xenopus oocytes
expressing individual VGKC subunits proved more sen-
sitive and showed that most patients did have anti-
bodies to one or the other of these channels (Hart et al.,
1997). This has recently been extended by binding of pa-
tient sera to relevant neural tissues with high expression
of VGKC, as well as to different Kv subunits expressed
on the surface of transfected mammalian cells, reaching
a higher sensitivity of detecting VGKC antibodies
(Kleopa et al., 2006).
VGKCs constitute one of the most ubiquitous and di-
verse group of ion channels found in the body (Jan and
Jan, 1997). Functional Kv channels are formed by homo-
tetramers or heterotetramers of a subunits (Catterall,
1988). The tetramer of K+ channel a subunits is often as-
sociated with an auxiliary b subunit, which can modify
the gating properties of the heteromultimeric channel
complex (MacKinnon, 1991). Heteromeric K+ channels
of different subunit stoichiometry may be localized to dif-
ferent subcellular compartments, presumably because
their channel properties are better suited for the physio-
logical requirements of those locations. Kva subunits are
glycoproteins with six transmembrane segments. The
S4 segment of each monomer serves as the voltage
sensor. The voltage-dependent inactivation process in-
volves conformational changes in the amino terminus
of any one of the four subunits (Doyle et al., 1998).
How autoantibodies impair VGKC function remains
unclear, but, as in the case of other antibodies to ion
channel proteins, they likely target extracellular epitopes
of the a subunit. This would explain why sera from pa-
tients bind poorly to denatured Kv subunits in western
blots (Kleopa et al., 2006). The human VGKC antibodies
bind to recombinant a subunits expressed as tetramers
at the cell membrane of transfected cells, but not to intra-
cellularly retained immature subunit proteins (Kleopa
et al., 2006). This may be due to the fact that they recog-
nize posttranslational modifications such as N-glycosyl-
ation, or tertiary structure that depends on subunit inter-
actions (Shi et al., 1996; Manganas and Trimmer, 2000).
At least in our studies so far, we could not detect any
reactivity of NMT sera to the Kvb subunit.
VGKC antibodies are heterogeneous and may bind to
multiple Kv subunits (Hart et al., 1997; Kleopa et al.,
2006). Although in most cases the autoantibodies be-
long to the IgG subclass, in rare occasions IgM VGKC
antibodies have been detected and had similar sup-
pressing effects on potassium channel currents (Kurono
et al., 2006). VGKC antibodies in NMT do not appear to
block the function of Shaker-type K+ channels directly,
since short incubation (up to 2 hr) of cultured neuronal
cell lines with IgG from NMT patients had no effect.However, when applied for several hours, they reduce
K+ channel current amplitudes without changing gating
kinetics (Sonoda et al., 1996; Nagado et al., 1999; Fig-
ure 5). Thus, antibodies in sera from NMT patients ap-
pear, in a mechanism independent of added comple-
ment, to accelerate channel turnover and degradation
of VGKC through crosslinking of the channels by diva-
lent antibodies (Tomimitsu et al., 2004).
Morvan’s Syndrome
In 1890, Morvan described ten patients with symptoms
of neuromyotonia, one of whom had severe insomnia
and mental confusion (see Serratrice and Azulay,
1994). This was first termed Morvan’s fibrillary chorea
because of the marked muscle fibrillations and myo-
clonic movements, but it is usually now called Morvan’s
syndrome. Reportedly extremely rare, it can be associ-
ated with heavy metal intoxication (gold, mercury), other
toxins, and also thymomas, hinting at an autoimmune
etiology. Over the last 10 years, about ten patients
have been reported in the English literature, of whom
around half had high titers of VGKC antibodies. Clini-
cally, the patients present with a combination of periph-
eral hyperexcitability with autonomic and CNS distur-
bance, but the relative contributions of these can differ
(Lee et al., 1998; Barber et al., 2000). VGKC antibodies
can be modestly or highly raised and in general patients
either improve spontaneously over time or respond
more quickly to immunosuppressive treatments, partic-
ularly plasma exchange (Halbach et al., 1987; Madrid
et al., 1996; Heidenreich and Vincent, 1998; Lee et al.,
1998; Liguori et al., 2001) or immunoadsorption (Antozzi
et al., 2005). The recognition that the CNS symptoms as
well as the more peripheral symptoms improved with
this treatment drew attention to the potential roles of
serum autoantibodies to ion channels in other CNS
diseases.
Limbic Encephalitis
An autoimmune, nonparaneoplastic VGKC antibody-
mediated disease affecting exclusively the CNS and
most prominently the limbic areas has recently been
recognized (Buckley et al., 2001; Vincent et al., 2004;
Thieben et al., 2004). The most striking examples are pa-
tients who develop, acutely or subacutely, memory loss
and confusion, leading over days or weeks to epileptic
seizures (either temporal lobe or partial complex sei-
zures). Cognitive impairment is profound with substan-
tial retrograde and anterograde memory loss. On mag-
netic resonance imagine (MRI) there is high signal in
the hippocampal regions(s) (Figure 5). This is usually
termed limbic encephalitis (LE) and previously has
been thought of as a paraneoplastic neurological condi-
tion with poor prognosis, due to the presence of an as-
sociated tumor, and poor response to treatments. In
contrast to the paraneoplastic form, VGKC antibody-as-
sociated LE cases do not usually have a tumor and can
respond well, albeit sometimes over weeks rather than
days, to immunotherapies (Vincent et al., 2004; Thieben
et al., 2004), with good recovery of memory and other
CNS functions. Interestingly, some of the patients have
evidence for rapid eye movement sleep behavioral dis-
order (Iranzo et al., 2006), indicating a relationship with
Morvan’s syndrome in whom sleep disorder is promi-
nent. However, in contrast to patients with Morvan’s
syndrome, LE patients lack clinical manifestations of
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(A) Antibodies in neuromyotonia downregulate Kv1.1 and -1.6 currents. Effects of serum from patients with acquired neuromyotonia (patients 1
and 2) on hKv1.1 (A and B) and 1.6 (C and D) expressed in CHO-K1 cells. Transfected CHO-K1 cells were cultured for 3 days with 2% serum from
the patients and controls. (A) and (C) show peak K+ current densities obtained at the test potential of +40 mV from the holding potential of
280 mV. (B) and (D) show conductance-voltage relationships by nonlinear regression fitting to the Boltzmann equation. *p < 0.05, **p < 0.01,
compared with two healthy controls. Numbers of cells are shown in parentheses. Values are mean 6 SEM. Taken from Nagado et al. (1999)
with permission. (E) Magnetic resonance imaging of a patient with VGKC antibody-associated limbic encephalitis showing increase signal (white)
in the medial temporal lobes and particularly the hippocampi. (F) Binding of sera (green) from patients with Morvan’s syndrome (MoS) or limbic
encephalitis (LE) to sciatic nerve teased fibers (Fa and Fb) or to hippocampal regions (Fc and Fd). Double staining with anti-Kv1.2 (Fa and Fb) or
anti-Kv1.1 (Fc and Fd) specific antibodies demonstrates the expression of Kv1.2 in peripheral myelinated axons, especially at the juxtapara-
nodes (arrows), juxta-incisures (arrowheads), and juxtamesaxons (open arrowheads). While there is no specific labeling with a control serum
(Fa), the serum from a patient with MoS (Fb) binds to the same areas colocalizing with Kv1.2. In the hippocampal CA3 area (Fc), Kv1.1 is strongly
expressed in the mossy fiber layer (mf) and much less in the stratum pyramidale (py), radiatum (rd), and oriens (or). The serum from a patient with
LE strongly labels the mf layer colocalizing with Kv1.1. In CA1 (Fd), Kv1.1 is strongly expressed in the rd and less in the or layers, and the LE serum
binds to the same areas colocalizing with Kv1.1. Merged images are shown in the right column, including nuclear staining (blue) to demonstrate
the different layers. Scale bars, 10 mm in Fa and Fb, 50 mm in Fc and Fd. Adapted with permission from Kleopa et al. (2006).peripheral nerve hyperexcitability, and most have nor-
mal peripheral electrophysiological studies as well
(Vincent et al., 2004).
VGKC Antibodies in Neuromyotonia, Morvan’s
Syndrome, and Limbic Encephalitis
Although VGKC antibody levels differ broadly between
the three syndromes, these alone are unlikely to provide
an explanation for the different clinical expression of the
diseases. In particular, the highest antibodies are found
in patients with LE, but these patients seldom have any
evidence of neuromyotonia. Morvan’s syndrome falls
between the other two in having intermediate levels of
VGKC antibodies and a broader range of symptoms,
but this does not explain why sleep disorder can be so
marked in these patients. As an aside, in each of these
conditions there are patients with typical features who
do not have detectable VGKC antibodies, indicating
that other antibodies may play a similar role.Kv channels are expressed widely in the central and
peripheral nervous systems but show a highly specific
localization of individual Kv1 subunits in each area that
may be functionally important. Kv1.1 and Kv1.2 are
coexpressed at the juxtaparanodal regions of the axons
surrounding the nodes of Ranvier (Wang et al., 1993; Ar-
royo and Scherer, 2000) (Figure 5). Here, they account
for the Ki current that can be recorded by patch clamp-
ing of myelinated axons (Safronov et al., 1993; Reid
et al., 1999) and contribute to the regulation of axonal
membrane excitability, preventing repetitive dis-
charges. Additional voltage-gated K+ conductances
have been recorded in mammalian axons, including
the slowly activating current, Ks (Roper and Schwarz,
1989; Safronov et al., 1993), ascribed to KCNQ2 ex-
pressed at the nodes (Devaux et al., 2004), and the fast
nodal current, Kf2, which may be generated by Kv3.1b
(Corrette et al., 1991; Devaux et al., 2003).
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VGKC subunits in different regions has emerged (Veh
et al., 1995), but the cerebellum and hippocampus
have received most attention due to the genetic disor-
ders associated with dysfunction of VGKC in these
areas, especially epilepsy and episodic ataxia (Browne
et al., 1994; Eunson et al., 2000). Kv1.1–1.6 are highly ex-
pressed in different combinations in the cerebellar mo-
lecular and granule cell layers as well as at the basket
cell terminals (Chung et al., 2001), and in specific layers
of the hippocampus that contain excitatory axon termi-
nals, most prominently in the molecular layer of the den-
tate gyrus, in the CA3 mossy fiber zone, and in the stra-
tum radiatum of CA1-3 (Sheng et al., 1994; Wang et al.,
1994; Monaghan et al., 2001) (Figure 5). K+ channels
play a major role in regulating the excitability of hippo-
campal neurons by modulating neurotransmitter re-
lease, postsynaptic responses to excitatory inputs, neu-
ronal spike properties, and firing frequency (Johnston
et al., 2000).
This complex expression pattern of Kv channels in the
CNS and PNS gives rise to the question of whether the
contrasting clinical phenotypes of NMT, Morvan’s
syndrome, or LE, each associated with antibodies to
dendrotoxin-binding VGKC, could be explained by dif-
ferences in their subunit specificity. Double immunohis-
tochemistry on different regions of the nervous system,
comparing the binding of commercial antibodies to indi-
vidual Kv1 subunits with that of sera from patients with
NMT, Morvan’s syndrome, or LE, showed that almost
all patients had Kv1.2 antibodies that could bind to the
juxtaparanodes and to regions in the CNS with high
Kv1.2 expression; a few only had Kv1.6 antibodies that
bound in the CNS, but only LE sera labeled the hippo-
campal areas that are enriched in excitatory, Kv1.1-pos-
itive axon terminals (Kleopa et al., 2006; Figure 5). These
results were confirmed by quantitative binding of sera to
the respective subunits expressed in transfected cells,
with Kv1.1-binding rates of 19.7%–38% for LE, as op-
posed to 0%–2.67% for NMT sera (Kleopa et al., 2006).
An insufficient number of Morvans’ syndrome sera
were investigated to draw conclusions regarding their
specificity, although Kv1.6 antibodies were predomi-
nant in one patient (Antozzi et al., 2005; Kleopa et al.,
2006).
Although these studies have provided a possible ex-
planation for the different clinical pictures, many ques-
tions remain. In particular, why the hippocampus should
be so vulnerable in limbic encephalitis (in Morvan’s syn-
drome there is seldom MRI evidence of inflammatory
changes in the hippocampus, and memory loss is less
evident) and whether the MRI findings indicate prior
breakdown of the blood-brain barrier or antibody-medi-
ated inflammatory changes in the hippocampus. Fur-
thermore, in most sera, regardless of the associated
phenotype, reactivity to more than one Kv subunit type
can be detected, indicating that patients may have
a mixture of individual antibodies that have specific ac-
tivity to different subunits, or individual antibodies that
crossreact with multiple subunits (Hart et al., 1997;
Kleopa et al., 2006). Further factors, such as the acces-
sibility of different peripheral or central neural tissues to
circulating Kv1 antibodies, as well as the repertoire of
Kv1 channels expressed in each area with partiallyoverlapping function, may also determine the threshold
for developing neuronal dysfunction.
Further investigation of autoimmune VGKC disorders
will require animal models, which are currently being de-
veloped. Immunization against isolated Kv subunits may
indicate which particular roles individual subunits and
the respective autoantibodies play in different areas of
the nervous system but will require techniques to ensure
that the blood-brain barrier or the peripheral nerve sep-
tate-like paranodal junctions are made ‘‘leaky’’ in order
to allow the antibodies to gain access, and will not
explain why they do so in the patients. Furthermore,
more than one Kv subunit may have to be compromised
in each area in order to produce a phenotype, since an-
imal models in which the juxtaparanodal concentration
of Kv1.1 and Kv1.2 is impaired, including mice deficient
in the juxtaparanodal adhesion molecules TAG-1 (Poliak
et al., 2003; Traka et al., 2003) or Caspr2 (Poliak et al.,
2003) show no hyperexcitability of peripheral nerves.
On the other hand, Kv1.1 null mice develop spontaneous
seizures with hippocampal excitability (Smart et al.,
1998), underscoring the crucial role of this subunit alone.
Other Channelopathies
Autoimmune channelopathies are expanding and clini-
cally important (e.g., see Buckley and Vincent, 2005).
Rasmussen’s encephalitis is a severe form of intractable
childhood epilepsy that is usually restricted to one hemi-
sphere and leads to marked cognitive decline. The dis-
ease is associated with inflammatory and degenerative
changes in the cerebral cortex and is extremely resistant
to treatment. Hemispherectomy may be the only way of
preventing seizure activity and helping to protect the
child against increasing cognitive problems. Antibodies
to glutamate receptor 3 (GluR3) were first detected in
Rasmussen’s encephalitis following the serendipitous
observation that immunization of rabbits with the
GluR3 extracellular domain resulted in inflammation of
the cortex and seizure activity (Rogers et al., 1994). The
mechanisms by which these antibodies might cause sei-
zures and cortical damage are several (reviewed in detail
by McNamara et al., 1999), and immunization against
GluR3 in rats confirms their potential pathogenicity (Le-
vite and Hermelin, 1999), but the frequency of these anti-
bodies in patients is more controversial (Watson et al.,
2004), and they may not be specific for Rasmussen’s en-
cephalitis (Mantegazza et al., 2002). Moreover, there is
accumulating evidence that Rasmussen’s encephalitis
is a T cell-mediated disorder (Bien et al., 2005), and it
may be that the GluR3 antibodies are secondary to the
neuronal damage evoked by frequent prolonged sei-
zures rather than causing it (although plasma exchange
was strikingly effective in some patients [e.g., Rogers
et al., 1994]).
Another target of potential interest is the NMDA re-
ceptor. A portion of the patients with systemic lupus er-
ythematosus develop neuropsychiatric disorders with
varying degrees of headache, learning difficulties, sei-
zures, or psychosis. This condition is associated with
serum antibodies to DNA, ribosomal, and phospholipid
antigens, but none of these antibodies have been con-
firmed as pathogenic toward the CNS. However, a recent
study found that anti-DNA antibodies crossreact with
the NR2A and NR2B subunits of the NMDA receptor
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gio et al., 2001). The crossreacting antibodies were
shown to cause hippocampal cell death when injected
into mouse brains, and animals immunized with the
NR2A peptide developed high titers of specific NR2A an-
tibodies, which were able to gain access to the hippo-
campus (but only when they were given intraperitoneal
lipopolysaccharide, which is thought to open the
blood-brain barrier). These animals performed less well
in water maze and T maze tasks (Kowal et al., 2004).
The antibodies may act by stimulation of the NMDA
receptor, leading to glutamate-induced neurotoxicity.
Finally, an intriguing new channelopathy has emerged
among patients with an inflammatory neurological dis-
ease, thought to be similar to multiple sclerosis. Over
60% of patients with neuromyelitis optica, but very few
of those with multiple sclerosis, have serum antibodies
that bind to the pia, microvessels, choroid plexus, and
Virchow-Robbin spaces on brain tissue sections. The
target of these antibodies has now been defined as
aquaporin-4, one of the water channels (Lennon et al.,
2005). Aquaporin-4 is located in the astrocytic endfeet,
and its distribution is determined by agrin-mediated
interactions with the cell membrane. Whether these
antibodies are directly pathogenic and how they act
in vivo is not yet determined.
Conclusions
Autoimmune channelopathies have come a long way
since autoantibodies to AChR were first shown in the
1970s and now extend to the autonomic and central ner-
vous systems. They offer interesting parallels to the ge-
netic disorders that involve mutations in the same chan-
nels (Table 1), but they are usually adult-onset disorders,
some of which present relatively acutely, and some of
which may improve spontaneously. In most cases the
underlying cause of the disease is not clear, but a tumor
(thymoma or small cell lung cancer) must always be con-
sidered. The antibodies act mainly by increasing the
turnover of the target antigen, and by complement-
mediated damage in MG; direct block of function by an-
tibodies binding to the agonist site or ion channel pore
is more variable. In each of these conditions, clinical
data demonstrate wide heterogeneity of disease ex-
pression, and experimental data strongly suggest that
there are compensatory changes that might help to ex-
plain some of this phenotypic variation. These changes
may also, of course, occur in the genetic channelopa-
thies, and understanding the mechanisms by which
they happen in vivo may point the way to therapeutic
possibilities.
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